Affiliation:
1. Omsk State Medical University
Abstract
Irritable bowel syndrome is a very urgent problem in modern gastroenterology. A deeper understanding of the ethology and pathogenesis, the variety of drugs for the treatment of IBS gives hope for the possibility of effective control over the disease in the near future. The article provides a brief overview of the latest advances in the study of irritable bowel syndrome, which were reported at the next UEG Week Virtual 2020, held in October 2020.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference37 articles.
1. Flacco M.E., Manzoli L., De Giorgio R., Gasbarrini A., Cicchetti A., Bravi F. et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a metaanalysis. Eur. Rev. Med. Pharmacol. Sci. 2019. Vol. 23, No. 7. P. 2986–3000.
2. Zhang F., Xiang W., Li C.Y., Li S.C. Economic burden of irritable bowel syndrome in China // World J. Gastroenterol. 2016. Vol. 22, No. 47. P. 10450–10460.
3. Peery A.F., Crockett S.D., Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019. Vol. 156, No. 1. P. 254–272.
4. Jabbar K.S., Dolan B., Eklund L., Wising C., Ermund A., Johansson A. et al. Association between Brachyspira and irritable bowel syndrome with diarrhoea. Gut. 2020. Vol. 0. P. 1–13.
5. Hampson DJ. The spirochete Brachyspira pilosicoli, enteric pathogen of animals and humans. Clin. Microbiol. Rev. 2018. Vol. 31, No. 1. e00087–17.